Oppenheimer Issues Positive Forecast for Artivion (NYSE:AORT) Stock Price

Artivion (NYSE:AORT) had its target price increased by equities research analysts at Oppenheimer from $30.00 to $32.00 in a report released on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 11.46% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a report on Friday, September 27th. Stifel Nicolaus increased their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, JMP Securities began coverage on shares of Artivion in a research note on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.00.

Artivion Price Performance

Shares of AORT opened at $28.71 on Friday. The firm has a fifty day moving average price of $26.19 and a 200 day moving average price of $25.15. The stock has a market cap of $1.20 billion, a PE ratio of -136.71 and a beta of 1.75. Artivion has a 1-year low of $13.18 and a 1-year high of $30.00. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $98.02 million during the quarter, compared to analysts’ expectations of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. As a group, sell-side analysts anticipate that Artivion will post 0.2 EPS for the current year.

Insider Transactions at Artivion

In related news, VP Matthew A. Getz sold 9,420 shares of Artivion stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total value of $238,420.20. Following the transaction, the vice president now directly owns 34,116 shares in the company, valued at $863,475.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now directly owns 34,116 shares of the company’s stock, valued at $863,475.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,109 shares of company stock worth $951,935 over the last 90 days. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in Artivion in the second quarter valued at $28,000. RiverPark Advisors LLC acquired a new stake in shares of Artivion in the second quarter valued at about $55,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after purchasing an additional 4,154 shares during the period. RW Investment Management LLC purchased a new stake in Artivion during the second quarter worth about $219,000. Finally, Intech Investment Management LLC acquired a new position in Artivion during the second quarter worth about $253,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.